Subcutaneous Injectable Drugs Hypersensitivity and Desensitization : Insulin and Monoclonal Antibodies - 30/09/17
, Min Jung Lee, MD bRésumé |
Injectable drugs, including monoclonal antibodies, are becoming crucial components in the management of chronic diseases. The most common side effects are local reactions at the site of administration. With the increased and prolonged use of these medications, we are seeing increased reports of hypersensitivity reactions. The aim of this article is to discuss the signs and symptoms of these reactions as well as management, which may involve desensitization for 3 commonly encountered injectable drugs: tumor necrosis factor-α inhibitors (etanercept and adalimumab), insulin, and omalizumab.
Le texte complet de cet article est disponible en PDF.Keywords : Adalimumab, Etanercept, Omalizumab, Insulin, Injection site reactions, Systemic hypersensitivity reactions, MoAbs, TNF-α inhibitors
Plan
| The authors do not have any commercial or financial conflict of interest and any funding sources relevant to this article. |
Vol 37 - N° 4
P. 761-771 - novembre 2017 Retour au numéro
Article précédent
- Delayed Cutaneous Hypersensitivity Reactions to Antibiotics : Management with Desensitization
- Caitlin M.G. McNulty, Miguel A. Park
- Progestogen Hypersensitivity : An Evidence-Based Approach to Diagnosis and Management in Clinical Practice
- Dinah Foer, Kathleen M. Buchheit
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?